- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01109888
Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF)
Study Overview
Status
Intervention / Treatment
Detailed Description
30 patients undergoing IVF using a GnRH antagonist protocol that present with a high response to gonadotrophin stimulation, will be randomized into one of two groups: group A - withdrawal of gonadotrophin support and continue a daily dose of 0.25 mg of the GnRH antagonist. group B - withdrawal of gonadotrophin support and continue a double daily dose of 0.5 mg of the GnRH antagonist.
The main outcome measures will be the duration of coasting (days)and the rate of serum E2 drop (%).
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:30 women undergoing IVF cycle with GnRH Antagonist protocol under 35 years old.
E2 higher than 3000 pg/ml. -
Exclusion Criteria: 3 or more failed fresh IVF cycles.
-
Study Plan
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cetrotide
|
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Endocrine System Diseases
- Disease
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Syndrome
- Ovarian Hyperstimulation Syndrome
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Cetrorelix
Other Study ID Numbers
- 12101967
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cetrotide
-
Aristotle University Of ThessalonikiCompleted
-
PfizerCompleted
-
Pınar Özcan CenksoyUnknown
-
Assistance Publique - Hôpitaux de ParisMerckSerono PharmaceuticalsCompleted
-
University of OxfordOxford Fertility Limited, United KingdomUnknown
-
Cairo UniversityCompletedOther Complications Associated With Artificial FertilizationEgypt
-
Institute for Human Reproduction (IHR)Completed
-
Benha UniversityUnknown
-
Virginia Center for Reproductive MedicineCompletedOvarian Hyperstimulation SyndromeUnited States
-
EugoniaUnknownOvarian Hyperstimulation SyndromeGreece